Abstract:Allogeneic hematopoietic cell transplantation (alloHCT) is a standard curative therapy for a variety of benign and malignant hematological diseases. Previously, patients who underwent alloHCT were at high risk for complications with potentially life-threatening toxicities, including a variety of opportunistic infections as well as acute and chronic manifestations of graft-versus-host disease (GVHD), where the transplanted immune system can produce inflammatory damage to the patient. With recent advances, including newer conditioning regimens, advances in viral and fungal infection prophylaxis, and novel GVHD prophylactic and treatment strategies, improvements in clinical outcomes have steadily improved. One modality with great potential that has yet to be fully realized is targeting the microbiome to further improve clinical outcomes.In recent years, the intestinal microbiota, which includes bacteria, fungi, viruses, and other microbes that reside within the intestinal tract, has become established as a potent modulator of alloHCT outcomes. The composition of intestinal bacteria, in particular, has been found in large multicenter prospective studies to be strongly associated with GVHD, treatment-related mortality, and overall survival. Murine studies have demonstrated a causal relationship between intestinal microbiota injury and aggravated GVHD, and more recently, clinical interventional studies of repleting the intestinal microbiota with fecal microbiota transplantation have emerged as effective therapies for GVHD. How the composition of the intestinal bacterial microbiota, which is often highly variable in alloHCT patients, can modulate GVHD and other outcomes is not fully understood. Recent studies, however, have begun to make substantial headway, including identifying particular bacterial subsets and/or bacterial-derived metabolites that can mediate harm or benefit. Here, the authors review recent studies that have improved our mechanistic understanding of the relationship between the microbiota and alloHCT outcomes, as well as studies that are beginning to establish strategies to modulate the microbiota with the hope of optimizing clinical outcomes.

Therapeutic Perspectives and Mechanistic Insights of Phage Therapy in Allotransplantation

Current State of Compassionate Phage Therapy

Phage Therapy in Lung Transplantation: Current Status and Future Possibilities

Early clinical experience of bacteriophage therapy in 3 lung transplant recipients

Development of Host Immune Response to Bacteriophage in a Lung Transplant Recipient on Adjunctive Phage Therapy for a Multidrug-Resistant Pneumonia

Phage therapy: A targeted approach to overcoming antibiotic resistance

Improving the Safety and Efficacy of Phage Therapy from the Perspective of Phage-Mammal Interactions.

Phage Therapy: A Different Approach to Fight Bacterial Infections

Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective

The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation

Phage therapy: From biological mechanisms to future directions

Phage therapy in gut microbiome

Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler

Phage therapy: an alternative treatment modality for MDR bacterial infections

Biological foundations of successful bacteriophage therapy

Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections

Limitations of Phage Therapy and Corresponding Optimization Strategies: A Review

Phage Therapy: Consider the Past, Embrace the Future

Phage Therapy Approaches to Reducing Pathogen Persistence and Transmission in Animal Production Environments: Opportunities and Challenges

Phage Therapy for Nontuberculous Mycobacteria: Challenges and Opportunities

From Infection to Colonization: the Role of Microbiota in Transplantation